drugset
drugset / Trial / NCT02078219

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

NCT02078219 ↗

Phase 2 Completed 204 enrolled AstraZeneca Ardea Biosciences, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in greater reduction of sUA compared to placebo.

Timeline

Start
2014-01-05
Primary completion
2015-03-13
Completion
2015-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopurinol Small molecule 200 mg Oral
Subject Verinurad Small molecule 7.5 mg Oral
Subject Verinurad Small molecule 12.5 mg Oral
Subject Verinurad Small molecule 15 mg Oral

Indications

gout